Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
01:57pm, Monday, 08'th Jul 2024
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
01:47pm, Monday, 08'th Jul 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
PARA/Skydance Agreement, LLY to Acquire MORF, NOW Downgrade
11:45am, Monday, 08'th Jul 2024
Paramount (PARA) enters a definitive merger agreement with Skydance Media. Eli Lilly (LLY) is acquiring Morphic Therapeutics (MORF) for $3.2B cash.
Eli Lilly to acquire Morphic in $3.2B deal
11:30am, Monday, 08'th Jul 2024
Pharmaceutical giant Eli Lilly (LLY) has reached an agreement to purchase biopharmaceutical company Morphic (MORF) in a deal valued at $3.2 billion. This strategic move marks a notable expansion in El
More Records Highs for Eli Lilly Stock After Buyout
10:14am, Monday, 08'th Jul 2024
Eli Lilly And Co (NYSE:LLY) announced earlier today it will acquire Morphic Holding (NASDAQ:MORF) for $3.2 billion in cash, expanding its inflammatory bowel disease (IBD) drug portfolio.
Eli Lilly Buys Morphic for $3.2B
09:59am, Monday, 08'th Jul 2024
Eli Lilly (LLY) agreed to buy biopharmaceutical firm Morphic (MORF) at a significant premium, sending shares of Morphic skyrocketing Monday.
Wall Street Favors These Four ETFs With Stellar Ratings
09:46am, Monday, 08'th Jul 2024
When it comes to investing, individual exchange-traded funds (ETFs) aren't a one-size-fits-all financial vehicle as there are plenty of funds to choose from and the number of long-term possibilities i
Eli Lilly Buys Bowel Disease Drug Developer Morphic In $3.2 Billion Deal
09:37am, Monday, 08'th Jul 2024
Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for inflammatory
Eli Lilly acquires IBD drug developer Morphic in $3.2bn deal
09:33am, Monday, 08'th Jul 2024
Eli Lilly and Co (NYSE:LLY) has struck a deal to acquire Morphic Holding Inc (NASDAQ:MORF), a maker of inflammatory bowel disease (IBD) drugs, for approximately $3.2 billion. On a per-share basis the
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
08:55am, Monday, 08'th Jul 2024
Monday, Eli Lilly And Co LLY agreed to acquire Morphic Holding Inc MORF for $57 per share in cash, an aggregate of approximately $3.2 billion.
3 No-Brainer Stocks to Buy in July
08:00am, Monday, 08'th Jul 2024
Eli Lilly could be headed for a market capitalization above $1 trillion. Regeneron has overcome bumps and shows no signs of slowing down.
Eli Lilly to acquire Morphic Therapeutics for $3.2 billion in cash
07:26am, Monday, 08'th Jul 2024
CNBC's Joe Kernen reports on the latest news.
Eli Lilly to Buy Morphic for $3.2 Billion. Morphic Stock Surges 78%.
07:24am, Monday, 08'th Jul 2024
Eli Lilly agrees to pay $57 a share for Morphic, or a 79% premium to the stock's closing price of $31.84 on Friday.
Morphic's stock rockets after $3.2 billion buyout deal with Eli Lilly
06:56am, Monday, 08'th Jul 2024
Shares of Morphic Holding Inc. MORF, +0.03% rocketed 76% in premarket trading Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly & Co. LLY, +1.83% in a cash
Eli Lilly to acquire Morphic Holding for $3.2 billion
06:52am, Monday, 08'th Jul 2024
Eli Lilly will acquire Morphic Holding for $3.2 billion, the companies said on Monday.
